{
    "abstract": "Background: Invasive meningococcal disease has its highest incidence in infants. Co-administration of serogroup B (4CMenB) and quadrivalent conjugate (MenACWY-CRM) vaccines could protect against 5 clinically-relevant meningococcal serogroups. Methods: This phase 3b, open, multicenter study (NCT02106390), conducted in Mexico and Argentina, enrolled and randomized (1:1:1) 750 healthy infants to receive either 4CMenB co-administered with MenACWY-CRM (4CMenB/MenACWY group), 4CMenB (4CMenB group), or MenACWY-CRM alone (MenACWY group) at ages 3, 5, 7 and 13 months. Non-inferiority of immune responses of co-administration to single administration of vaccines was assessed at 1 month post-booster dose (primary objective). Immunogenicity was evaluated pre- and 1 month post-primary and booster vaccinations using human serum bactericidal assay (hSBA). Safety was assessed. Results: At 1 month post-booster vaccination, between-group hSBA geometric mean titer (GMT) ratios ranged from 0.89 to 1.03 for serogroup B strains (group 4CMenB/MenACWY over 4CMenB), and from 1.05 to 2.48 for ACWY serogroups (group 4CMenB/MenACWY over MenACWY). The lower limit of the 2-sided 95% confidence intervals for all GMT ratios was >0.5; the primary objective was demonstrated. Across all groups and serogroup B strains, 68\u2013100% and 87\u2013100% of children had hSBA titers \u22655 at 1 month post-primary and booster vaccination, respectively. For serogroups ACWY, \u226596% (post-primary vaccination) and \u226598% (post-booster vaccination) of children in all groups had hSBA titers \u22654. Post-booster vaccination, GMTs increased \u22655.99-fold from pre-booster values for each strain/serogroup. Solicited adverse events (AEs) were more frequent in groups 4CMenB/MenACWY and 4CMenB than in MenACWY; incidence of all other AEs was similar between groups. Serious AEs were reported for 6, 13, and 11 participants in groups 4CMenB/MenACWY, 4CMenB, and MenACWY, respectively; 1 (group 4CMenB) was considered vaccine-related. Conclusion: Immune responses elicited by co-administration of 4CMenB and MenACWY-CRM was non-inferior to single immunization. Co-administration of vaccines was immunogenic and well tolerated in infants. ClinicalTrials.gov: NCT02106390.",
    "author_highlights": [
        {
            "endOffset": 18045,
            "sentence": "4CMenB and MenACWY-CRM were (co)administered at ages 3, 5, 7, 13 months (M)",
            "startOffset": 17970
        },
        {
            "endOffset": 18152,
            "sentence": "At 14 M, immune responses to co-administration were non-inferior to single administration of each vaccine.",
            "startOffset": 18046
        },
        {
            "endOffset": 18261,
            "sentence": "Across groups, 68\u2013100% (8 M) and 87\u2013100% (14 M) of children had hSBA titers \u22655 for serogroup B test strains.",
            "startOffset": 18153
        },
        {
            "endOffset": 18355,
            "sentence": "Across groups, \u226596% (8 M) and \u226598% (14 M) of children had hSBA titers \u22654 for serogroups ACWY.",
            "startOffset": 18262
        },
        {
            "endOffset": 18419,
            "sentence": "Co-administration of 4CMenB and MenACWY-CRM was well tolerated.",
            "startOffset": 18356
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Gabutti"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Stefanati"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Kuhdari"
                }
            ],
            "firstpage": "E116",
            "issn": "11212233",
            "lastpage": "E120",
            "pub_year": 2015,
            "title": "Epidemiology of Neisseria meningitidis infections: Case distribution by age and relevance of carriage",
            "volume": "56"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martin\u00f3n-Torres"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.03.041",
            "firstpage": "S12",
            "issn": "1054139X",
            "lastpage": "S20",
            "pmid": "27449145",
            "pub_year": 2016,
            "title": "Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements",
            "volume": "59"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "McIntyre"
                },
                {
                    "first": "Katherine L.",
                    "initial": "K.L.",
                    "last": "O'Brien"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Diederik",
                    "initial": "D.",
                    "last": "Van De Beek"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61187-8",
            "firstpage": "1703",
            "issn": "01406736",
            "lastpage": "1711",
            "pmid": "23141619",
            "pub_year": 2012,
            "title": "Effect of vaccines on bacterial meningitis worldwide",
            "volume": "380"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Caroline L.",
                    "initial": "C.L.",
                    "last": "Trotter"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.04.063",
            "firstpage": "B51",
            "issn": "0264410X",
            "lastpage": "B63",
            "pmid": "19477562",
            "pub_year": 2009,
            "title": "Global epidemiology of meningococcal disease",
            "volume": "27"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Pedro",
                    "initial": "P.",
                    "last": "Alarc\u00f3n"
                },
                {
                    "first": "Josefina",
                    "initial": "J.",
                    "last": "Carlos"
                },
                {
                    "first": "Dominique A.",
                    "initial": "D.A.",
                    "last": "Caugant"
                },
                {
                    "first": "Hannah",
                    "initial": "H.",
                    "last": "Christensen"
                },
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Debbag"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "De Wals"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Ech\u00e1niz-Aviles"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Head"
                },
                {
                    "first": "Daphne",
                    "initial": "D.",
                    "last": "Holt"
                },
                {
                    "first": "Hajime",
                    "initial": "H.",
                    "last": "Kamiya"
                },
                {
                    "first": "Samir K.",
                    "initial": "S.K.",
                    "last": "Saha"
                },
                {
                    "first": "Sergey",
                    "initial": "S.",
                    "last": "Sidorenko"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Trotter"
                },
                {
                    "first": "Julio A.",
                    "initial": "J.A.",
                    "last": "V\u00e1zquez Moreno"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "von Gottberg"
                },
                {
                    "first": "Marco A.P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1080/14760584.2017.1258308",
            "firstpage": "313",
            "issn": "14760584",
            "lastpage": "328",
            "pmid": "27820969",
            "pub_year": 2017,
            "title": "The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection",
            "volume": "16"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Stephen I.",
                    "initial": "S.I.",
                    "last": "Pelton"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.04.012",
            "firstpage": "S3",
            "issn": "1054139X",
            "lastpage": "S11",
            "pmid": "27449148",
            "pub_year": 2016,
            "title": "The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines",
            "volume": "59"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Rabab Z.",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar A.",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1186/1478-7954-11-17",
            "issn": "14787954",
            "pub_year": 2013,
            "title": "Global epidemiology of invasive meningococcal disease",
            "volume": "11"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Carmen",
                    "initial": "C.",
                    "last": "Baccarini"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Ternouth"
                },
                {
                    "first": "Heather",
                    "initial": "H.",
                    "last": "Wieffer"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Vyse"
                }
            ],
            "doi": "10.4161/hv.22302",
            "firstpage": "162",
            "issn": "21645515",
            "lastpage": "171",
            "pmid": "23108355",
            "pub_year": 2013,
            "title": "The changing epidemiology of meningococcal disease in North America 1945-2010",
            "volume": "9"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Marco Aur\u00e9lio P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": "Luz Elena Espinosa",
                    "initial": "L.E.E.",
                    "last": "De Los Monteros"
                },
                {
                    "first": "Eduardo Luis",
                    "initial": "E.L.",
                    "last": "L\u00f3pez"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "S\u00e0ez-Llorens"
                },
                {
                    "first": "Ana Paula",
                    "initial": "A.P.",
                    "last": "Lemos"
                },
                {
                    "first": "Sarbelio",
                    "initial": "S.",
                    "last": "Moreno-Espinosa"
                },
                {
                    "first": "Silvia Gonz\u00e1lez",
                    "initial": "S.G.",
                    "last": "Ayala"
                },
                {
                    "first": "Juan Pablo",
                    "initial": "J.P.",
                    "last": "Torres"
                },
                {
                    "first": "Jos\u00e9 Cassio",
                    "initial": "J.C.",
                    "last": "De Moraes"
                },
                {
                    "first": "Julio Alberto",
                    "initial": "J.A.",
                    "last": "V\u00e1zquez"
                }
            ],
            "doi": "10.1586/14760584.2013.814879",
            "firstpage": "903",
            "issn": "14760584",
            "lastpage": "915",
            "pmid": "23909747",
            "pub_year": 2013,
            "title": "The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative",
            "volume": "12"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Jin Soo",
                    "initial": "J.S.",
                    "last": "Lee"
                },
                {
                    "first": "Julio A.",
                    "initial": "J.A.",
                    "last": "V\u00e1zquez"
                },
                {
                    "first": "Godwin",
                    "initial": "G.",
                    "last": "Enwere"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Hajime",
                    "initial": "H.",
                    "last": "Kamiya"
                },
                {
                    "first": "Hwang Min",
                    "initial": "H.M.",
                    "last": "Kim"
                },
                {
                    "first": "Dae Sun",
                    "initial": "D.S.",
                    "last": "Jo"
                }
            ],
            "doi": "10.1016/j.vaccine.2016.10.022",
            "firstpage": "5855",
            "issn": "0264410X",
            "lastpage": "5862",
            "pmid": "27780631",
            "pub_year": 2016,
            "title": "Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative",
            "volume": "34"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Crum-Cianflone"
                },
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Sullivan"
                }
            ],
            "doi": "10.1007/s40121-016-0107-0",
            "firstpage": "89",
            "issn": "21938229",
            "lastpage": "112",
            "pub_year": 2016,
            "title": "Meningococcal Vaccinations",
            "volume": "5"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Cooper"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Detora"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Stoddard"
                }
            ],
            "doi": "10.1586/erv.10.147",
            "firstpage": "21",
            "issn": "14760584",
            "lastpage": "33",
            "pmid": "21162617",
            "pub_year": 2011,
            "title": "Menveo\u00ae: A novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and y",
            "volume": "10"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Stan L.",
                    "initial": "S.L.",
                    "last": "Block"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Shepard"
                },
                {
                    "first": "Hartley",
                    "initial": "H.",
                    "last": "Garfield"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1097/INF.0000000000000965",
            "firstpage": "e48",
            "issn": "08913668",
            "lastpage": "e59",
            "pmid": "26479973",
            "pub_year": 2016,
            "title": "Immunogenicity and Safety of a 3-and 4-dose Vaccination Series of a Meningococcal ACWY Conjugate Vaccine in Infants: Results of a Phase 3b, Randomized, Open-label Trial",
            "volume": "35"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Roberto",
                    "initial": "R.",
                    "last": "Gasparini"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Pavitra",
                    "initial": "P.",
                    "last": "Keshavan"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1097/INF.0000000000000930",
            "firstpage": "81",
            "issn": "08913668",
            "lastpage": "93",
            "pmid": "26398743",
            "pub_year": 2016,
            "title": "Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration",
            "volume": "35"
        },
        "b0075": {
            "authors": [
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Diaz-Mitoma"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Anemona"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Ceddia"
                }
            ],
            "doi": "10.1007/s10096-009-0848-8",
            "firstpage": "259",
            "issn": "09349723",
            "lastpage": "267",
            "pmid": "20033465",
            "pub_year": 2010,
            "title": "Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers",
            "volume": "29"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Terry M.",
                    "initial": "T.M.",
                    "last": "Nolan"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Nissen"
                },
                {
                    "first": "Aftab",
                    "initial": "A.",
                    "last": "Naz"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Shepard"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Hohenboken"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.4161/hv.27051",
            "firstpage": "280",
            "issn": "21645515",
            "lastpage": "289",
            "pmid": "24220326",
            "pub_year": 2014,
            "title": "Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age",
            "volume": "10"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "Tregnaghi"
                },
                {
                    "first": "Pio",
                    "initial": "P.",
                    "last": "Lopez"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Stamboulian"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Gra\u00f1a"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.ijid.2014.03.1390",
            "firstpage": "22",
            "issn": "12019712",
            "lastpage": "30",
            "pmid": "24980467",
            "pub_year": 2014,
            "title": "Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers",
            "volume": "26"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Vega",
                    "initial": "V.",
                    "last": "Masignani"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                }
            ],
            "doi": "10.1080/14760584.2017.1308828",
            "firstpage": "433",
            "issn": "14760584",
            "lastpage": "451",
            "pmid": "28375029",
            "pub_year": 2017,
            "title": "Emerging experience with meningococcal serogroup B protein vaccines",
            "volume": "16"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Gian Vincenzo",
                    "initial": "G.V.",
                    "last": "Zuccotti"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.4161/hv.28666",
            "firstpage": "1993",
            "issn": "21645515",
            "lastpage": "2004",
            "pmid": "25424809",
            "pub_year": 2014,
            "title": "A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB",
            "volume": "10"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Gian Vincenzo",
                    "initial": "G.V.",
                    "last": "Zuccotti"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Michelangelo",
                    "initial": "M.",
                    "last": "Barone"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                }
            ],
            "doi": "10.4161/hv.29218",
            "firstpage": "2005",
            "issn": "21645515",
            "lastpage": "2014",
            "pmid": "25424810",
            "pub_year": 2014,
            "title": "A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II): Effects of variations of the OMV and protein content on immunogenicity and reactogenicity",
            "volume": "10"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Kimura"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61961-8",
            "firstpage": "825",
            "issn": "01406736",
            "lastpage": "835",
            "pmid": "23324563",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials",
            "volume": "381"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Nicoletta",
                    "initial": "N.",
                    "last": "Gossger"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Finn"
                },
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Nicola",
                    "initial": "N.",
                    "last": "Principi"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Etienne",
                    "initial": "E.",
                    "last": "Sokal"
                },
                {
                    "first": "Birgitta",
                    "initial": "B.",
                    "last": "Becker"
                },
                {
                    "first": "Dorothee",
                    "initial": "D.",
                    "last": "Kieninger"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Kimura"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1001/jama.2012.85",
            "firstpage": "573",
            "issn": "00987484",
            "lastpage": "582",
            "pmid": "22318278",
            "pub_year": 2012,
            "title": "Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial",
            "volume": "307"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Dawson"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Holland"
                },
                {
                    "first": "Tessa M.",
                    "initial": "T.M.",
                    "last": "John"
                },
                {
                    "first": "Anita",
                    "initial": "A.",
                    "last": "Evans"
                },
                {
                    "first": "Karen L.",
                    "initial": "K.L.",
                    "last": "Telford"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Philipp",
                    "initial": "P.",
                    "last": "Oster"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1086/656741",
            "firstpage": "1127",
            "issn": "10584838",
            "lastpage": "1137",
            "pmid": "20954968",
            "pub_year": 2010,
            "title": "Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy",
            "volume": "51"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Sydel R.",
                    "initial": "S.R.",
                    "last": "Parikh"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Charlotte",
                    "initial": "C.",
                    "last": "Ward"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "White"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                }
            ],
            "doi": "10.1016/S0140-6736(16)31921-3",
            "firstpage": "2775",
            "issn": "01406736",
            "lastpage": "2782",
            "pmid": "28100432",
            "pub_year": 2016,
            "title": "Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study",
            "volume": "388"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Riordan"
                },
                {
                    "first": "John M.",
                    "initial": "J.M.",
                    "last": "Watson"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1136/archdischild-2015-308928",
            "firstpage": "91",
            "issn": "00039888",
            "lastpage": "95",
            "pmid": "26672098",
            "pub_year": 2016,
            "title": "Enter B and W: Two new meningococcal vaccine programmes launched",
            "volume": "101"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Marco Aurelio",
                    "initial": "M.A.",
                    "last": "Marco"
                },
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martinon-Torres"
                },
                {
                    "first": "Lily Yin",
                    "initial": "L.Y.",
                    "last": "Weckx"
                },
                {
                    "first": "Edson Duarte",
                    "initial": "E.D.",
                    "last": "Moreira"
                },
                {
                    "first": "Eduardo Jorge",
                    "initial": "E.J.",
                    "last": "da Fonseca Lima"
                },
                {
                    "first": "Ilhem",
                    "initial": "I.",
                    "last": "Mensi"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Calabresi"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.002",
            "firstpage": "2052",
            "issn": "0264410X",
            "lastpage": "2059",
            "pmid": "28318767",
            "pub_year": 2017,
            "title": "Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial",
            "volume": "35"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "O'Ryan"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Stoddard"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1007/s40265-013-0155-7",
            "firstpage": "15",
            "issn": "00126667",
            "lastpage": "30",
            "pmid": "24338083",
            "pub_year": 2014,
            "title": "A multi-component meningococcal serogroup B vaccine (4CMenB): The clinical development program",
            "volume": "74"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Balmer"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2005.01.051",
            "firstpage": "2222",
            "issn": "0264410X",
            "lastpage": "2227",
            "pmid": "15755600",
            "pub_year": 2005,
            "title": "Meningococcal surrogates of protection - Serum bactericidal antibody activity",
            "volume": "23"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Keith S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                },
                {
                    "first": "William",
                    "initial": "W.",
                    "last": "Johnston"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Gill"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1097/INF.0b013e31823dce5c",
            "firstpage": "64",
            "issn": "08913668",
            "lastpage": "74",
            "pmid": "22094635",
            "pub_year": 2012,
            "title": "Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants",
            "volume": "31"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martin\u00f3n-Torres"
                },
                {
                    "first": "Marco Aurelio P.",
                    "initial": "M.A.P.",
                    "last": "Safadi"
                },
                {
                    "first": "Alfonso Carmona",
                    "initial": "A.C.",
                    "last": "Martinez"
                },
                {
                    "first": "Pilar Infante",
                    "initial": "P.I.",
                    "last": "Marquez"
                },
                {
                    "first": "Juan Carlos Tejedor",
                    "initial": "J.C.T.",
                    "last": "Torres"
                },
                {
                    "first": "Lily Yin",
                    "initial": "L.Y.",
                    "last": "Weckx"
                },
                {
                    "first": "Edson Duarte",
                    "initial": "E.D.",
                    "last": "Moreira"
                },
                {
                    "first": "Ilhem",
                    "initial": "I.",
                    "last": "Mensi"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Calabresi"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.05.023",
            "firstpage": "3548",
            "issn": "0264410X",
            "lastpage": "3557",
            "pmid": "28533054",
            "pub_year": 2017,
            "title": "Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial",
            "volume": "35"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Kirsten P.",
                    "initial": "K.P.",
                    "last": "Perrett"
                },
                {
                    "first": "Karen J.",
                    "initial": "K.J.",
                    "last": "Ford"
                },
                {
                    "first": "Tessa M.",
                    "initial": "T.M.",
                    "last": "John"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Pace"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "Langley"
                },
                {
                    "first": "Shelley",
                    "initial": "S.",
                    "last": "McNeil"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Ceddia"
                },
                {
                    "first": "Alessandra",
                    "initial": "A.",
                    "last": "Anemona"
                },
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Dobson"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1001/jama.2007.29-c",
            "firstpage": "173",
            "issn": "00987484",
            "lastpage": "184",
            "pmid": "18182599",
            "pub_year": 2008,
            "title": "Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: A randomized controlled trial",
            "volume": "299"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Pavitra",
                    "initial": "P.",
                    "last": "Keshavan"
                },
                {
                    "first": "Jo Anne",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "Linda",
                    "initial": "L.",
                    "last": "Han"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                }
            ],
            "doi": "10.1080/21645515.2015.1136040",
            "firstpage": "1300",
            "issn": "21645515",
            "lastpage": "1310",
            "pmid": "26829877",
            "pub_year": 2016,
            "title": "Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants",
            "volume": "12"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Saez-Llorens"
                },
                {
                    "first": "Diana Catalina Aguilera",
                    "initial": "D.C.A.",
                    "last": "Vaca"
                },
                {
                    "first": "Katia",
                    "initial": "K.",
                    "last": "Abarca"
                },
                {
                    "first": "Emmanuelle",
                    "initial": "E.",
                    "last": "Maho"
                },
                {
                    "first": "Maria Gabriela",
                    "initial": "M.G.",
                    "last": "Gra\u00f1a"
                },
                {
                    "first": "Esther",
                    "initial": "E.",
                    "last": "Heijnen"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Smolenov"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1080/21645515.2015.1029686",
            "firstpage": "1507",
            "issn": "21645515",
            "lastpage": "1517",
            "pmid": "25969894",
            "pub_year": 2015,
            "title": "Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents",
            "volume": "11"
        },
        "b0170": {
            "authors": [
                {
                    "first": "P. T.",
                    "initial": "P.T.",
                    "last": "Beernink"
                },
                {
                    "first": "D. A.",
                    "initial": "D.A.",
                    "last": "Caugant"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Welsch"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Koeberling"
                },
                {
                    "first": "D. M.",
                    "initial": "D.M.",
                    "last": "Granoff"
                }
            ],
            "doi": "10.1086/597806",
            "firstpage": "1360",
            "issn": "00221899",
            "lastpage": "1368",
            "pmid": "19302008",
            "pub_year": 2009,
            "title": "Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa",
            "volume": "199"
        },
        "b0175": {
            "authors": [
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Wang"
                },
                {
                    "first": "Amanda",
                    "initial": "A.",
                    "last": "Cohn"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Lubomira",
                    "initial": "L.",
                    "last": "Andrew"
                },
                {
                    "first": "Xin",
                    "initial": "X.",
                    "last": "Zhao"
                },
                {
                    "first": "Jessica R.",
                    "initial": "J.R.",
                    "last": "MacNeil"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Schmink"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Muzzi"
                },
                {
                    "first": "Stefania",
                    "initial": "S.",
                    "last": "Bambini"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Murphy"
                },
                {
                    "first": "Susan K.",
                    "initial": "S.K.",
                    "last": "Hoiseth"
                },
                {
                    "first": "Kathrin U.",
                    "initial": "K.U.",
                    "last": "Jansen"
                },
                {
                    "first": "Annaliesa S.",
                    "initial": "A.S.",
                    "last": "Anderson"
                },
                {
                    "first": "Lee H.",
                    "initial": "L.H.",
                    "last": "Harrison"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Leonard W.",
                    "initial": "L.W.",
                    "last": "Mayer"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.04.092",
            "firstpage": "4739",
            "issn": "0264410X",
            "lastpage": "4744",
            "pub_year": 2011,
            "title": "Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States",
            "volume": "29"
        },
        "b0180": {
            "authors": [
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Marzia Monica",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Biolchi"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.3201/eid2202.150369",
            "firstpage": "309",
            "issn": "10806040",
            "lastpage": "311",
            "pmid": "26811872",
            "pub_year": 2016,
            "title": "Effectiveness of meningococcal B vaccine against endemic hypervirulent neisseria meningitidis W strain, England",
            "volume": "22"
        },
        "b0185": null,
        "b0190": {
            "authors": [
                {
                    "first": "Eva",
                    "initial": "E.",
                    "last": "Hong"
                },
                {
                    "first": "Marzia Monica",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Ala Eddine",
                    "initial": "A.E.",
                    "last": "Deghmane"
                },
                {
                    "first": "Maurizio",
                    "initial": "M.",
                    "last": "Comanducci"
                },
                {
                    "first": "Brunella",
                    "initial": "B.",
                    "last": "Brunelli"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.12.022",
            "firstpage": "1113",
            "issn": "0264410X",
            "lastpage": "1116",
            "pmid": "23261039",
            "pub_year": 2013,
            "title": "Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?",
            "volume": "31"
        },
        "b0195": {
            "authors": [
                {
                    "first": "Marco Aurelio",
                    "initial": "M.A.",
                    "last": "Marco"
                },
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martinon-Torres"
                },
                {
                    "first": "Lily Yin",
                    "initial": "L.Y.",
                    "last": "Weckx"
                },
                {
                    "first": "Edson Duarte",
                    "initial": "E.D.",
                    "last": "Moreira"
                },
                {
                    "first": "Eduardo Jorge",
                    "initial": "E.J.",
                    "last": "da Fonseca Lima"
                },
                {
                    "first": "Ilhem",
                    "initial": "I.",
                    "last": "Mensi"
                },
                {
                    "first": "Marco",
                    "initial": "M.",
                    "last": "Calabresi"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                }
            ],
            "doi": "10.1016/j.vaccine.2017.03.002",
            "firstpage": "2052",
            "issn": "0264410X",
            "lastpage": "2059",
            "pmid": "28318767",
            "pub_year": 2017,
            "title": "Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial",
            "volume": "35"
        },
        "b0200": {
            "authors": [
                {
                    "first": "\u00c1ngela",
                    "initial": "\u00c1.",
                    "last": "Gentile"
                },
                {
                    "first": "Julia",
                    "initial": "J.",
                    "last": "Bakir"
                },
                {
                    "first": "Mar\u00eda Rosa",
                    "initial": "M.R.",
                    "last": "Agosti"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Ensinck"
                },
                {
                    "first": "Hector",
                    "initial": "H.",
                    "last": "Abate"
                },
                {
                    "first": "Andrea Gajo",
                    "initial": "A.G.",
                    "last": "Gane"
                },
                {
                    "first": "Alejandro Santill\u00e1n",
                    "initial": "A.S.",
                    "last": "Iturres"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Efron"
                },
                {
                    "first": "Mabel",
                    "initial": "M.",
                    "last": "Regueira"
                },
                {
                    "first": "Ricardo",
                    "initial": "R.",
                    "last": "R\u00fcttimann"
                }
            ],
            "doi": "10.1097/INF.0000000000001429",
            "firstpage": "296",
            "issn": "08913668",
            "lastpage": "300",
            "pmid": "27902653",
            "pub_year": 2017,
            "title": "Meningococcal disease in children in Argentina A 3-year active sentinel hospital surveillance study",
            "volume": "36"
        },
        "b0205": null,
        "b0210": {
            "authors": [
                {
                    "first": "Marco Aur\u00e9lio P.",
                    "initial": "M.A.P.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "O'Ryan"
                },
                {
                    "first": "Maria Teresa",
                    "initial": "M.T.",
                    "last": "Valenzuela Bravo"
                },
                {
                    "first": "Maria Cristina C.",
                    "initial": "M.C.C.",
                    "last": "Brandileone"
                },
                {
                    "first": "Maria Cec\u00edlia O.",
                    "initial": "M.C.O.",
                    "last": "Gorla"
                },
                {
                    "first": "Ana Paula S.",
                    "initial": "A.P.S.",
                    "last": "de Lemos"
                },
                {
                    "first": "Gabriela",
                    "initial": "G.",
                    "last": "Moreno"
                },
                {
                    "first": "Julio A.",
                    "initial": "J.A.",
                    "last": "Vazquez"
                },
                {
                    "first": "Eduardo L.",
                    "initial": "E.L.",
                    "last": "L\u00f3pez"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2015.10.055",
            "firstpage": "6529",
            "issn": "0264410X",
            "lastpage": "6536",
            "pmid": "26597036",
            "pub_year": 2015,
            "title": "The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations",
            "volume": "33"
        },
        "b0215": {
            "authors": [
                {
                    "first": "Ricardo Walter",
                    "initial": "R.W.",
                    "last": "Ruttimann"
                },
                {
                    "first": "Angela",
                    "initial": "A.",
                    "last": "Gentile"
                },
                {
                    "first": "Mercedes Macias",
                    "initial": "M.M.",
                    "last": "Parra"
                },
                {
                    "first": "Xavier",
                    "initial": "X.",
                    "last": "Saez-Llorens"
                },
                {
                    "first": "Marco Aurelio Palazzi",
                    "initial": "M.A.P.",
                    "last": "Safadi"
                },
                {
                    "first": "Maria Elena",
                    "initial": "M.E.",
                    "last": "Santolaya"
                }
            ],
            "doi": "10.1097/INF.0000000000000228",
            "firstpage": "284",
            "issn": "08913668",
            "lastpage": "290",
            "pmid": "24463807",
            "pub_year": 2014,
            "title": "A consensus statement: Meningococcal disease among infants, children and adolescents in Latin America",
            "volume": "33"
        }
    },
    "body_text": [
        {
            "endOffset": 35423,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Two unsolicited AEs (pyrexia in group 4CMenB and atopic dermatitis in group MenACWY) led to early study termination.",
            "startOffset": 35307,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 30071,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For this sample size, the overall power to reject all 8 null hypotheses associated with the primary confirmatory objective was 86.9%, while for a sample of 150 children in each group, an overall power of 67.6% was calculated.",
            "startOffset": 29846,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 36337,
            "parents": [],
            "secId": "s0060",
            "sentence": "Co-administration of the vaccines induced robust immune responses to all serogroup and strains following both primary and booster vaccination and was well tolerated.",
            "startOffset": 36172,
            "title": "Discussion"
        },
        {
            "endOffset": 26037,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0060": {
                    "endOffset": 25997,
                    "startOffset": 25993
                },
                "b0135": {
                    "endOffset": 25976,
                    "startOffset": 25972
                }
            },
            "secId": "s0015",
            "sentence": "The 4CMenB [27] and MenACWY-CRM [12] vaccines had previously been described.",
            "startOffset": 25961,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29194,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "All infants were observed for at least 30 min after each vaccination for any immediate reactions.",
            "startOffset": 29097,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 31461,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Baseline characteristics were well matched between study groups (Table S1).",
            "startOffset": 31386,
            "title": "Demographics"
        },
        {
            "endOffset": 37778,
            "parents": [],
            "secId": "s0060",
            "sentence": "However, as expected, \u226596% of children had hSBA titers \u22658 following the booster dose.",
            "startOffset": 37693,
            "title": "Discussion"
        },
        {
            "endOffset": 39722,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 39662,
                    "startOffset": 39652
                },
                "b0110": {
                    "endOffset": 39662,
                    "startOffset": 39652
                },
                "b0150": {
                    "endOffset": 39662,
                    "startOffset": 39652
                }
            },
            "secId": "s0060",
            "sentence": "The incidence of unsolicited AEs was comparable between groups and to that previously reported for both vaccines in this age category [14,22,30] and did not increase with the number of doses administered.",
            "startOffset": 39518,
            "title": "Discussion"
        },
        {
            "endOffset": 27503,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objective evaluated the non-inferiority of the immune responses to 4CMenB and MenACWY-CRM when administered concomitantly compared to either vaccine alone, at 1 month after the completion of the vaccination series at 3, 5, 7, and 13 months of age in healthy infants, as measured by serum bactericidal assay using human serum as the source of complement (hSBA).",
            "startOffset": 27131,
            "title": "Study objectives"
        },
        {
            "endOffset": 23791,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 23790,
                    "startOffset": 23783
                },
                "b0100": {
                    "endOffset": 23790,
                    "startOffset": 23783
                },
                "b0105": {
                    "endOffset": 23790,
                    "startOffset": 23783
                },
                "b0110": {
                    "endOffset": 23790,
                    "startOffset": 23783
                },
                "b0115": {
                    "endOffset": 23790,
                    "startOffset": 23783
                }
            },
            "secId": "s0005",
            "sentence": "The vaccine demonstrated immunogenicity and an acceptable safety profile in infants in clinical trials [19\u201323].",
            "startOffset": 23680,
            "title": "Introduction"
        },
        {
            "endOffset": 39063,
            "parents": [],
            "secId": "s0060",
            "sentence": "The 2 meningococcal vaccines were well tolerated in our study when either co-administered or administered alone in infants and no safety issues were raised.",
            "startOffset": 38907,
            "title": "Discussion"
        },
        {
            "endOffset": 22273,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 22250,
                    "startOffset": 22243
                },
                "b0025": {
                    "endOffset": 22250,
                    "startOffset": 22243
                },
                "b0035": {
                    "endOffset": 22250,
                    "startOffset": 22243
                },
                "b0045": {
                    "endOffset": 22272,
                    "startOffset": 22269
                }
            },
            "secId": "s0005",
            "sentence": "Serogroups B, C, and W cause the majority of meningococcal disease in Africa (with serogroup A disease being practically eliminated following a mass vaccination program in the meningitis belt) [4,5,7] and Latin America [9].",
            "startOffset": 22050,
            "title": "Introduction"
        },
        {
            "endOffset": 28594,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Immune responses to vaccination were assessed by hSBA against each of the ACWY serogroups (for MenACWY-CRM) and against 4 serogroup B reference strains specific for vaccine components: H44/76 for factor H binding protein (fHbp), 5/99 for Neisserial adhesin A (NadA), M10713 for neisseria heparin binding antigen (NHBA) and NZ98/254 for porin A protein (PorA) expressed by outer membrane vesicles (for 4CMenB).",
            "startOffset": 28185,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 39330,
            "parents": [],
            "refoffsets": {
                "b0195": {
                    "endOffset": 39329,
                    "startOffset": 39325
                }
            },
            "secId": "s0060",
            "sentence": "Following each vaccination, higher rates of solicited AEs were reported in groups receiving 4CMenB vaccine compared to the group receiving MenACWY-CRM alone, similarly with observations from a study assessing co-administration of 4CMenB and MenC-CRM in infants [39].",
            "startOffset": 39064,
            "title": "Discussion"
        },
        {
            "endOffset": 36936,
            "parents": [],
            "secId": "s0060",
            "sentence": "Our study also showed that immunogenicity of MenACWY-CRM is not impacted by its co-administration with 4CMenB.",
            "startOffset": 36826,
            "title": "Discussion"
        },
        {
            "endOffset": 38656,
            "parents": [],
            "refoffsets": {
                "b0180": {
                    "endOffset": 38655,
                    "startOffset": 38651
                }
            },
            "secId": "s0060",
            "sentence": "Moreover, 4CMenB is believed to be able to induce cross-protection against hypervirulent serogroup W isolates currently circulating in England and Wales, which possess alleles for NadA-2/3 peptide variants [36].",
            "startOffset": 38445,
            "title": "Discussion"
        },
        {
            "endOffset": 28849,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0140": {
                    "endOffset": 28769,
                    "startOffset": 28765
                }
            },
            "secId": "s0025",
            "sentence": "An hSBA titer \u22654 is considered the surrogate of protection for serogroup C [28] and this threshold is generally extended to the other meningococcal serogroups.",
            "startOffset": 28690,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 29634,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Serious AEs (SAEs), AEs leading to withdrawal from the study, and medically attended AEs were recorded throughout the study.",
            "startOffset": 29510,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 32021,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Therefore, the primary confirmatory objective was demonstrated.",
            "startOffset": 31958,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 38129,
            "parents": [],
            "refoffsets": {
                "b0165": {
                    "endOffset": 37988,
                    "startOffset": 37984
                }
            },
            "secId": "s0060",
            "sentence": "In our study, post-booster hSBA GMTs for serogroup A were significantly higher in group 4CMenB/MenACWY compared with group MenACWY, which seems to confirm previous results obtained in different age groups [33] suggesting a degree of cross\u2013protection conferred by the administration of 4CMenB, which has shared expression of antigens with MenACWY-CRM.",
            "startOffset": 37779,
            "title": "Discussion"
        },
        {
            "endOffset": 34616,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The most frequently reported solicited systemic AE was persistent crying, reported for 41\u201352%, 43\u201358%, and 27\u201336% of children across the 4 vaccinations in groups 4CMenB/MenACWY, 4CMenB, and MenACWY; grade 3 systemic AEs were rare.",
            "startOffset": 34386,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 39517,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 39516,
                    "startOffset": 39509
                },
                "b0150": {
                    "endOffset": 39516,
                    "startOffset": 39509
                }
            },
            "secId": "s0060",
            "sentence": "However, the incidence of solicited AEs was similar between the 2 groups receiving 4CMenB and with that from other studies in which the vaccine was administered alone to infants [22,30].",
            "startOffset": 39331,
            "title": "Discussion"
        },
        {
            "endOffset": 35969,
            "parents": [],
            "secId": "s0060",
            "sentence": "This is the first study to assess co-administration of 4CMenB and MenACWY-CRM in infants.",
            "startOffset": 35880,
            "title": "Discussion"
        },
        {
            "endOffset": 35869,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "No deaths were reported during the study.",
            "startOffset": 35828,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26470,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from the parents/legal guardians of each infant included in the study before first vaccination.",
            "startOffset": 26337,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32290,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 1 month post\u2013primary vaccination, in both the 4CMenB/MenACWY and the 4CMenB groups, the percentages of infants with hSBA titers \u22655 were 100% (fHbp), 100% (NadA), \u226568% (NHBA), and \u226596% (PorA).",
            "startOffset": 32096,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22470,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 22469,
                    "startOffset": 22465
                }
            },
            "secId": "s0005",
            "sentence": "In the Asia-Pacific region, serogroup A is more prominent in low-income countries, while C, W, and Y are prevalent in developed regions, and a mixed epidemiology is reported for IMD in China [10].",
            "startOffset": 22274,
            "title": "Introduction"
        },
        {
            "endOffset": 25184,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Participants were healthy infants aged 3 months (85\u2013119 days) at the time of the first vaccination, for whom informed consent had been obtained from parents/legal guardians.",
            "startOffset": 25011,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26947,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The 38 participants who were already enrolled were followed-up for the occurrence of solicited and unsolicited adverse events (AEs), and data collected were excluded from all analyses, except for safety analyses.",
            "startOffset": 26735,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32672,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Similar trends were observed for the percentage of infants with hSBA titers \u22658 for each of the serogroup B strains (Table S2).",
            "startOffset": 32546,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 31206,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "A total of 750 infants were enrolled, 744 received at least 1 study vaccination and 610 completed the study.",
            "startOffset": 31098,
            "title": "Demographics"
        },
        {
            "endOffset": 21961,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 21960,
                    "startOffset": 21955
                },
                "b0030": {
                    "endOffset": 21960,
                    "startOffset": 21955
                },
                "b0035": {
                    "endOffset": 21960,
                    "startOffset": 21955
                }
            },
            "secId": "s0005",
            "sentence": "Their prevalence can vary greatly geographically and has changed over the years following introduction of meningococcal vaccines [5\u20137].",
            "startOffset": 21826,
            "title": "Introduction"
        },
        {
            "endOffset": 24838,
            "parents": [],
            "secId": "s0005",
            "sentence": "A lay language graphical summary contextualizing the results and impact of our study is displayed in the Focus on Patient Section (Fig. 1).",
            "startOffset": 24699,
            "title": "Introduction"
        },
        {
            "endOffset": 32545,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 1 month post-booster vaccination, \u226599% (fHbp), \u226597% (NadA), 87% (NHBA), and \u226598% (PorA) of the children in groups receiving 4CMenB had hSBA titers \u22655.",
            "startOffset": 32392,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 36632,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 36597,
                    "startOffset": 36593
                },
                "b0100": {
                    "endOffset": 36569,
                    "startOffset": 36562
                },
                "b0105": {
                    "endOffset": 36569,
                    "startOffset": 36562
                },
                "b0110": {
                    "endOffset": 36569,
                    "startOffset": 36562
                },
                "b0115": {
                    "endOffset": 36569,
                    "startOffset": 36562
                },
                "b0150": {
                    "endOffset": 36631,
                    "startOffset": 36627
                }
            },
            "secId": "s0060",
            "sentence": "Immune responses to serogroup B strains in group 4CMenB/MenACWY and 4CMenB were comparable and in-line with previous reports for the administration of 4CMenB in infants, according to different schedules at 2, 4, 6, 12 months [20\u201323], at 2, 3, 4, 12 months [19], and at 2\u00bd, 3\u00bd, 5, 11 months [30].",
            "startOffset": 36337,
            "title": "Discussion"
        },
        {
            "endOffset": 25459,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Infants with previous immunization with a meningococcal vaccine, who had a known or suspected disease caused by N. meningitidis, or had previously been exposed to an individual with laboratory-confirmed N. meningitidis infection/colonization were not eligible for enrolment.",
            "startOffset": 25185,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33109,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 1 month post-primary vaccination, \u226596% of infants in groups 4CMenB/MenACWY and MenACWY had hSBA titers \u22654 and \u22658 against each of the ACWY serogroups.",
            "startOffset": 32957,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37450,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 37449,
                    "startOffset": 37442
                },
                "b0155": {
                    "endOffset": 37449,
                    "startOffset": 37442
                }
            },
            "secId": "s0060",
            "sentence": "The immune responses observed in our study following the administration of MenACWY-CRM at 3, 5, 7, and 13 months of age further confirm the strong antibody responses to infant immunization, including when MenACWY-CRM is administered with routine pediatric vaccines [14,31].",
            "startOffset": 37177,
            "title": "Discussion"
        },
        {
            "endOffset": 28185,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Blood samples (\u223c5 mL) were collected pre- and 1 month post-primary and booster vaccinations (Fig. 2).",
            "startOffset": 28084,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 28961,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In our study, we used an hSBA titer \u22655 as a threshold for the evaluation of the immune response to serogroup B.",
            "startOffset": 28850,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 35027,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Across all timepoints, unsolicited AEs were reported for 31\u201362% of participants in group 4CMenB/MenACWY, 40\u201366% of participants in group 4CMenB, and 20\u201362% of participants in group MenACWY (Table S4).",
            "startOffset": 34827,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 34267,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The most frequently reported solicited local AE in all groups and across all vaccinations was tenderness, for 59\u201365% and 36\u201348% of participants in group 4CMenB/MenACWY following 4CMenB and MenACWY-CRM vaccination, for 60\u201370% in group 4CMenB and 27\u201331% of children in group MenACWY (Fig. 3, Table 4).",
            "startOffset": 33968,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22049,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 22048,
                    "startOffset": 22043
                },
                "b0040": {
                    "endOffset": 22048,
                    "startOffset": 22043
                }
            },
            "secId": "s0005",
            "sentence": "Most IMD in Europe, North America, and Australia is caused by serogroups B and C [6,8].",
            "startOffset": 21962,
            "title": "Introduction"
        },
        {
            "endOffset": 22565,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 22564,
                    "startOffset": 22559
                },
                "b0030": {
                    "endOffset": 22564,
                    "startOffset": 22559
                }
            },
            "secId": "s0005",
            "sentence": "The use of meningococcal vaccines significantly decreased the incidence of IMD worldwide [3,6].",
            "startOffset": 22470,
            "title": "Introduction"
        },
        {
            "endOffset": 33517,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 1 month post-booster vaccination, 100% and \u226598% of participants in group 4CMenB/MenACWY and 98% and 96% of infants in group MenACWY had hSBA titers \u22658 and \u22654, respectively (Table 3 and Table S3).",
            "startOffset": 33319,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35202,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Overall, 37%, 41%, and 11% of unsolicited AEs occurring in groups 4CMenB/MenACWY, 4CMenB, and MenACWY, were considered as at least possibly related to vaccination (Table S4).",
            "startOffset": 35028,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 40296,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 40295,
                    "startOffset": 40289
                },
                "b0205": {
                    "endOffset": 40295,
                    "startOffset": 40289
                }
            },
            "secId": "s0060",
            "sentence": "Alongside Chile, Argentina is the latest South American country to implement quadrivalent meningococcal vaccination in its national immunization programs [5,41].",
            "startOffset": 40135,
            "title": "Discussion"
        },
        {
            "endOffset": 41705,
            "parents": [],
            "secId": "s0065",
            "sentence": "Immune responses to 4CMenB and MenACWY-CRM vaccine antigens when co\u2013administered were non-inferior to those elicited by separate administration according to a 3+1 schedule in infants, at 3, 5, 7, and 13 months of age.",
            "startOffset": 41488,
            "title": "Conclusions"
        },
        {
            "endOffset": 21699,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 21698,
                    "startOffset": 21695
                }
            },
            "secId": "s0005",
            "sentence": "IMD-caused morbidity and mortality is significant, and fatality rates can reach 10% despite the use of adequate antibiotic treatment [4].",
            "startOffset": 21562,
            "title": "Introduction"
        },
        {
            "endOffset": 25011,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase 3b, open-label, randomized trial, conducted in 7 centers in Mexico and Argentina between June 2014 and October 2016.",
            "startOffset": 24878,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27112,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The trial was registered at www.clinicaltrials.gov (NCT02106390) and a protocol summary is available from https://www.gsk-clinicalstudyregister.com/study/205240#ps.",
            "startOffset": 26948,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29362,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Solicited local and systemic AEs and unsolicited AEs were recorded on diary cards by the infants\u2019 parents/legally acceptable guardians for 7 days post-each vaccination.",
            "startOffset": 29194,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 32957,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Post-booster vaccination, GMTs in the 2 groups increased \u226516- (fHbp), \u22659.6- (NadA), \u22655.99- (NHBA), and \u226511-fold (PorA) compared with pre-booster values (Table 2).",
            "startOffset": 32795,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 27816,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Non-inferiority was demonstrated if the lower limits (LLs) of the 2\u2013sided 95% CIs for the between-group ratios of hSBA geometric mean titers (GMTs) (Group 4CMenB/MenACWY versus Group 4CMenB and Group 4CMenB/MenACWY versus Group MenACWY) were > 0.5 for all 4 serogroup B indicator strains and all ACWY serogroups.",
            "startOffset": 27504,
            "title": "Study objectives"
        },
        {
            "endOffset": 29058,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The more conservative titer of \u22658 was also used for each ACWY serogroup and serogroup B strains.",
            "startOffset": 28962,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32095,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Immunogenicity results were similar in both groups across all time points.",
            "startOffset": 32021,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40681,
            "parents": [],
            "secId": "s0060",
            "sentence": "The co-administration of 4CMenB and MenACWY-CRM at 3, 5, 7, 13 months of age could alternate with the administration of other routine pediatric vaccines and, at the same time, reduce the number of visits to the clinic and associated costs.",
            "startOffset": 40442,
            "title": "Discussion"
        },
        {
            "endOffset": 25540,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Further exclusion criteria are presented in the Supplementary material, Text S1.",
            "startOffset": 25460,
            "title": "Study design and participants"
        },
        {
            "endOffset": 21561,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21560,
                    "startOffset": 21555
                },
                "b0010": {
                    "endOffset": 21560,
                    "startOffset": 21555
                },
                "b0015": {
                    "endOffset": 21560,
                    "startOffset": 21555
                }
            },
            "secId": "s0005",
            "sentence": "IMD incidence varies with age, with the highest rates being recorded in infants [1\u20133].",
            "startOffset": 21475,
            "title": "Introduction"
        },
        {
            "endOffset": 23000,
            "parents": [],
            "secId": "s0005",
            "sentence": "Co-administration of quadrivalent and serogroup B vaccines in infants could provide immunization against the 5 most relevant meningococcal serogroups during the first year of life, when the risk of IMD is the highest.",
            "startOffset": 22783,
            "title": "Introduction"
        },
        {
            "endOffset": 33940,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Within-group post-/pre-booster vaccination GMRs tended to be higher in the 4CMenB/MenACWY group than in the MenACWY group for all 4 meningococcal serogroups (Table 3).",
            "startOffset": 33773,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35780,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One participant in the 4CMenB group had an SAE (anemia at day 35 of the 1st vaccination, leading to hospitalization, recovered after 175 days) that was considered by the investigator to be at least possibly related to the study vaccine.",
            "startOffset": 35544,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24699,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study evaluated the immunogenicity and safety of the 4CMenB and MenACWY-CRM vaccines co-administered in healthy infants at 3, 5, 7, and 13 months of age, and assessed the non-inferiority of the immune response to the vaccines when co-administered compared to their separate administration.",
            "startOffset": 24405,
            "title": "Introduction"
        },
        {
            "endOffset": 22782,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 22781,
                    "startOffset": 22777
                }
            },
            "secId": "s0005",
            "sentence": "Several monovalent conjugate vaccines against serogroup C or A, 5 quadrivalent serogroup ACWY-conjugate vaccines and 2 vaccines against serogroup B strains are currently approved for use in different age groups [11].",
            "startOffset": 22566,
            "title": "Introduction"
        },
        {
            "endOffset": 21825,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 21824,
                    "startOffset": 21821
                }
            },
            "secId": "s0005",
            "sentence": "Six of the 12 known meningococcal serogroups (A, B, C, W, X and Y) are responsible for almost all meningococcal diseases [4].",
            "startOffset": 21700,
            "title": "Introduction"
        },
        {
            "endOffset": 40134,
            "parents": [],
            "refoffsets": {
                "b0210": {
                    "endOffset": 40133,
                    "startOffset": 40129
                }
            },
            "secId": "s0060",
            "sentence": "Although limited data are available due to poorer surveillance mechanisms, an IMD incidence rate of <0.1/100,000 inhabitants is estimated in Mexico, with most cases reported in infants [42].",
            "startOffset": 39944,
            "title": "Discussion"
        },
        {
            "endOffset": 40956,
            "parents": [],
            "secId": "s0060",
            "sentence": "The study has several potential limitations.",
            "startOffset": 40912,
            "title": "Discussion"
        },
        {
            "endOffset": 35543,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In total, 38 SAEs were reported for 6, 13, and 11 participants in groups 4CMenB/MenACWY, 4CMenB, and MenACWY (Table S4).",
            "startOffset": 35423,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 38286,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 38285,
                    "startOffset": 38281
                }
            },
            "secId": "s0060",
            "sentence": "For instance, African serogroup A, W and X isolates were shown to express fHbp with significant sequence similarity to the fHbp antigen used in 4CMenB [34].",
            "startOffset": 38130,
            "title": "Discussion"
        },
        {
            "endOffset": 29510,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "AEs were graded by severity (from mild to severe); the relationship between unsolicited AEs and study vaccination was assessed by the investigator.",
            "startOffset": 29363,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 30389,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The primary immunogenicity analyses were performed on the per-protocol set, which included all evaluable participants who received the study vaccine correctly and had immunogenicity data from a blood drawn collected according to the study protocol, up to the booster vaccination.",
            "startOffset": 30110,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 24057,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 24056,
                    "startOffset": 24049
                },
                "b0125": {
                    "endOffset": 24056,
                    "startOffset": 24049
                }
            },
            "secId": "s0005",
            "sentence": "Over a period of ten months following its introduction in the United Kingdom national infant immunization schedule, a real-life effectiveness of 82.9% (confidence interval [CI]: 24.1\u201395.2) against all serogroup B cases was estimated after 2 doses of 4CMenB [24,25].",
            "startOffset": 23792,
            "title": "Introduction"
        },
        {
            "endOffset": 30110,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Secondary objectives were descriptive.",
            "startOffset": 30072,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 32794,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "hSBA GMTs for all serogroup B strains were comparable between the 4CMenB/MenACWY and the 4CMenB groups at all timepoints.",
            "startOffset": 32673,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 34385,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The incidence of solicited local events did not increase with subsequent vaccinations in any of the groups (Table 4).",
            "startOffset": 34268,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 30528,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The secondary analyses were performed on the full analysis sets at each timepoint, including all exposed participants with available data.",
            "startOffset": 30390,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31756,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At 1 month post-booster vaccination, the between-group hSBA GMT ratios (group 4CMenB/MenACWY over group 4CMenB) for each serogroup B strains varied between 0.89 and 1.03, and the LLs of the associated 95% CIs were above the pre-specified non-inferiority margin of 0.5 (Table 1).",
            "startOffset": 31478,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37692,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 37691,
                    "startOffset": 37687
                }
            },
            "secId": "s0060",
            "sentence": "As previously observed in infants receiving MenACWY\u2013CRM primary vaccination, the decline in the percentage of infants with hSBA titers \u2265 8 before booster was more pronounced for serogroup A than for the other 3 meningococcal serogroups [32].",
            "startOffset": 37451,
            "title": "Discussion"
        },
        {
            "endOffset": 38907,
            "parents": [],
            "refoffsets": {
                "b0185": {
                    "endOffset": 38860,
                    "startOffset": 38856
                },
                "b0190": {
                    "endOffset": 38906,
                    "startOffset": 38902
                }
            },
            "secId": "s0060",
            "sentence": "When testing pooled sera from adolescents and infants vaccinated with 4CMenB, bactericidal antibody activity was observed against 45\u201390% of serogroup C, W and Y strains isolated in Europe and Brazil [37] and against African serogroup X isolates [38].",
            "startOffset": 38657,
            "title": "Discussion"
        },
        {
            "endOffset": 41349,
            "parents": [],
            "secId": "s0060",
            "sentence": "Reporting of AEs might have been biased by the open-label design.",
            "startOffset": 41284,
            "title": "Discussion"
        },
        {
            "endOffset": 23479,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 23478,
                    "startOffset": 23471
                },
                "b0070": {
                    "endOffset": 23478,
                    "startOffset": 23471
                },
                "b0075": {
                    "endOffset": 23478,
                    "startOffset": 23471
                },
                "b0080": {
                    "endOffset": 23478,
                    "startOffset": 23471
                },
                "b0085": {
                    "endOffset": 23478,
                    "startOffset": 23471
                }
            },
            "secId": "s0005",
            "sentence": "MenACWY-CRM has been shown to be immunogenic and well tolerated in infants when administered alone or with routine pediatric vaccines according to different schedules [13\u201317].",
            "startOffset": 23304,
            "title": "Introduction"
        },
        {
            "endOffset": 36826,
            "parents": [],
            "secId": "s0060",
            "sentence": "This suggests that co-administration of 4CMenB with MenACWY-CRM does not interfere with immune responses to any of the 4 serogroup B strains following primary or booster vaccination in infants.",
            "startOffset": 36633,
            "title": "Discussion"
        },
        {
            "endOffset": 25961,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was open-label due to differences in the presentation of the vaccines.",
            "startOffset": 25881,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31385,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The reported site closure led to the exclusion from immunogenicity analyses of 14, 12 and 12 participants in the 4CMenB/MenACWY, 4CMenB and MenACWY groups, respectively (Fig. 2).",
            "startOffset": 31207,
            "title": "Demographics"
        },
        {
            "endOffset": 33318,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Pre-booster vaccination, the percentages of children with hSBA titers above each of these thresholds were similar between the 2 groups, with lower values observed for serogroup A (58\u201365%) than for CWY (\u226577%).",
            "startOffset": 33110,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 34827,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "After each vaccination, fever was reported for 17\u201326%, 18\u201325%, and 4\u201311% of participants in the 4CMenB/MenACWY, 4CMenB, and MenACWY groups, with grade 3 fever reported in \u22641% of infants in each group (Table 4).",
            "startOffset": 34617,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 35827,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "All SAEs were recovered/resolved by study end.",
            "startOffset": 35781,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33772,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "For serogroup A, GMTs were higher in the 4CMenB/MenACWY than the MenACWY group, at 1 month post-primary and post-booster vaccinations, based on non-overlapping 95% CIs.",
            "startOffset": 33604,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41476,
            "parents": [],
            "secId": "s0060",
            "sentence": "Future studies should investigate the long-term persistence of immune response to co-administration of 4CMenB and MenACWY-CRM.",
            "startOffset": 41350,
            "title": "Discussion"
        },
        {
            "endOffset": 40912,
            "parents": [],
            "secId": "s0060",
            "sentence": "Our study clearly demonstrates the feasibility of co-administrating 2 meningococcal vaccines covering 5 of the 6 clinically-relevant serogroups, supporting the introduction of 4CMenB and MenACWY-CRM in infant immunization programs.",
            "startOffset": 40681,
            "title": "Discussion"
        },
        {
            "endOffset": 23303,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 23302,
                    "startOffset": 23295
                },
                "b0060": {
                    "endOffset": 23302,
                    "startOffset": 23295
                }
            },
            "secId": "s0005",
            "sentence": "The quadrivalent meningococcal conjugate vaccine using non-toxic diphtheria cross-reacting mutant (CRM197) as carrier protein (MenACWY-CRM; Menveo, GSK) is approved for use in more than 60 countries worldwide, and in infants as young as 2 months in several countries, including in Latin America [11,12].",
            "startOffset": 23000,
            "title": "Introduction"
        },
        {
            "endOffset": 29845,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 29753,
                    "startOffset": 29746
                },
                "b0145": {
                    "endOffset": 29753,
                    "startOffset": 29746
                }
            },
            "secId": "s0035",
            "sentence": "A sample size of 250 enrolled infants per group was calculated based on previous studies [21,29] and assuming a drop-out rate of 20% in order to ensure 200 evaluable infants in each group.",
            "startOffset": 29657,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 25792,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Enrolled infants were randomized (1:1:1) into 3 parallel groups to receive either 4CMenB concomitantly with MenACWY-CRM (Group 4CMenB/MenACWY), 4CMenB alone (Group 4CMenB), or MenACWY-CRM alone (Group MenACWY) at 3, 5, 7, and 13 months of age (Fig. 2).",
            "startOffset": 25540,
            "title": "Study design and participants"
        },
        {
            "endOffset": 28056,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary objectives assessed the immune responses to 4CMenB and MenACWY-CRM when co-administered versus separate administration (at 1 month post-primary vaccination and pre- and 1 month post- booster vaccinations), safety and tolerability.",
            "startOffset": 27816,
            "title": "Study objectives"
        },
        {
            "endOffset": 26601,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocol and informed consent form were approved by an Independent Ethics Committee/Institutional Review Board at each center.",
            "startOffset": 26471,
            "title": "Study design and participants"
        },
        {
            "endOffset": 26734,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "However, during the study, GCP compliance issues were identified at one of the sites (Text S2), which was closed on 19 January 2016.",
            "startOffset": 26602,
            "title": "Study design and participants"
        },
        {
            "endOffset": 41283,
            "parents": [],
            "secId": "s0060",
            "sentence": "Following the GCP violation occurring during the study, a larger than expected number of infants were excluded from most analyses, although this is not likely to have impacted the results, as the number of exclusions were balanced between the 3 study groups and the overall power to assess the confirmatory objective was >67%.",
            "startOffset": 40957,
            "title": "Discussion"
        },
        {
            "endOffset": 23679,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 23678,
                    "startOffset": 23674
                }
            },
            "secId": "s0005",
            "sentence": "The 4-component serogroup B meningococcal vaccine (4CMenB; Bexsero, GSK) is currently approved in 39 countries, including in infants from 2 months of age (in Europe and several other countries) [18].",
            "startOffset": 23480,
            "title": "Introduction"
        },
        {
            "endOffset": 32391,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Pre-booster vaccination, lower values were observed for NHBA and PorA, as compared to fHbp and NadA.",
            "startOffset": 32291,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 24405,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 24404,
                    "startOffset": 24400
                }
            },
            "secId": "s0005",
            "sentence": "Co-administration of 4CMenB and the serogroup C polysaccharide CRM197-conjugate (MenC-CRM) vaccines in Brazilian infants at 3, 5, and 12 months of age was recently shown to be immunogenic and well tolerated, and a non-inferior response to MenC-CRM was demonstrated when co-administered with 4CMenB compared to administration of MenC\u2013CRM alone [26].",
            "startOffset": 24057,
            "title": "Introduction"
        },
        {
            "endOffset": 41892,
            "parents": [],
            "secId": "s0065",
            "sentence": "Co-administration of the vaccines was immunogenic and well tolerated, supporting the implementation of concomitant meningococcal vaccinations in national immunization programs worldwide.",
            "startOffset": 41706,
            "title": "Conclusions"
        },
        {
            "endOffset": 39794,
            "parents": [],
            "refoffsets": {
                "b0200": {
                    "endOffset": 39793,
                    "startOffset": 39789
                }
            },
            "secId": "s0060",
            "sentence": "The burden of meningococcal disease remains important in Argentina [40].",
            "startOffset": 39722,
            "title": "Discussion"
        },
        {
            "endOffset": 41976,
            "parents": [],
            "secId": "s0070",
            "sentence": "Bexsero and Menveo are trademarks of the GSK group of companies.",
            "startOffset": 41912,
            "title": "Trademark statement"
        },
        {
            "endOffset": 35306,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Most of them were solicited local and systemic AEs continuing beyond the 7-day period post-vaccination.",
            "startOffset": 35203,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 40441,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 40440,
                    "startOffset": 40434
                },
                "b0215": {
                    "endOffset": 40440,
                    "startOffset": 40434
                }
            },
            "secId": "s0060",
            "sentence": "However, routine meningococcal vaccination remains an unmet medical need in many countries not only in Latin America, but also worldwide [5,43].",
            "startOffset": 40297,
            "title": "Discussion"
        },
        {
            "endOffset": 26156,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "At each vaccination, a 0.5 mL dose was administered intramuscularly in the left (4CMenB) or right (MenACWY-CRM) thigh.",
            "startOffset": 26038,
            "title": "Study design and participants"
        },
        {
            "endOffset": 21474,
            "parents": [],
            "secId": "s0005",
            "sentence": "Neisseria meningitidis causes invasive meningococcal disease (IMD) worldwide.",
            "startOffset": 21397,
            "title": "Introduction"
        },
        {
            "endOffset": 36171,
            "parents": [],
            "secId": "s0060",
            "sentence": "A 3+1 vaccination schedule of 4CMenB and MenACWY-CRM co-administered at 3, 5, 7, and 13 months of age elicited immune responses non-inferior to those induced by separate administration of each vaccine.",
            "startOffset": 35970,
            "title": "Discussion"
        },
        {
            "endOffset": 38444,
            "parents": [],
            "refoffsets": {
                "b0175": {
                    "endOffset": 38443,
                    "startOffset": 38439
                }
            },
            "secId": "s0060",
            "sentence": "A study conducted in the United States showed that fHbp, NadA and NHBA are shared among serogroup B, C and Y isolates causing IMD between 2000 and 2008 [35].",
            "startOffset": 38287,
            "title": "Discussion"
        },
        {
            "endOffset": 31075,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All analyses were performed using SAS version 9.1.",
            "startOffset": 31025,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33603,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "hSBA GMTs were similar between the 2 groups for the CWY serogroups at all timepoints.",
            "startOffset": 33518,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 37176,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 37175,
                    "startOffset": 37171
                }
            },
            "secId": "s0060",
            "sentence": "These results are consistent with previous studies demonstrating non-inferiority of immune responses to serogroup C for MenC-CRM when co\u2013administered with 4CMenB according to a 2+1 schedule in infants, versus its administration alone [26].",
            "startOffset": 36937,
            "title": "Discussion"
        },
        {
            "endOffset": 26336,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), Declaration of Helsinki, and all applicable local regulations.",
            "startOffset": 26156,
            "title": "Study design and participants"
        },
        {
            "endOffset": 25880,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Randomization was performed according to a randomization list and accounting for center.",
            "startOffset": 25792,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39943,
            "parents": [],
            "refoffsets": {
                "b0205": {
                    "endOffset": 39942,
                    "startOffset": 39938
                }
            },
            "secId": "s0060",
            "sentence": "Between 2012 and 2015, incidence rates of 0.44\u20130.72/100,000 inhabitants were recorded, with 64% of cases occurring in infants \u22649 months of age [41].",
            "startOffset": 39795,
            "title": "Discussion"
        },
        {
            "endOffset": 31025,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Similarly, the 2-sided 95% CIs for each between-group ratio of GMTs were constructed using the common estimate of error from an ANOVA of the log-transformed titers.",
            "startOffset": 30861,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 30860,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The hSBA titers were logarithmically transformed (base10); the GMTs and within group geometric mean ratios (GMRs) and associated 95% CIs were computed by exponentiating the corresponding mean and 95% CIs from an analysis of variance (ANOVA) of the log\u2013transformed titers, at each timepoint, with study groups and centers as factors.",
            "startOffset": 30528,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 28690,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "hSBA testing was performed at the Clinical Laboratory Sciences, GSK Vaccines, Marburg, Germany.",
            "startOffset": 28595,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 31957,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "For each of the ACWY serogroups, between-group hSBA GMT ratios (group 4CMenB/MenACWY over group MenACWY) varied between 1.05 and 2.48, with LLs above the pre-specified statistical criterion (Table 1).",
            "startOffset": 31757,
            "title": "Immunogenicity"
        }
    ],
    "docId": "S0264410X18314932",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "mermacpar@hotmail.com",
                "first": "Mercedes",
                "initial": "M.",
                "last": "Macias Parra"
            },
            {
                "email": "angelagentile@fibertel.com.ar",
                "first": "Angela",
                "initial": "A.",
                "last": "Gentile"
            },
            {
                "email": "jorge.vazquez@ainpad.com.mx",
                "first": "Jorge Alejandro",
                "initial": "J.A.",
                "last": "Vazquez Narvaez"
            },
            {
                "email": "vax_ar@yahoo.com",
                "first": "Alejandro",
                "initial": "A.",
                "last": "Capdevila"
            },
            {
                "email": "angelminguez04@yahoo.com.ar",
                "first": "Angel",
                "initial": "A.",
                "last": "Minguez"
            },
            {
                "email": "monica.carrascal@caimed.com",
                "first": "Monica",
                "initial": "M.",
                "last": "Carrascal"
            },
            {
                "email": "arnold.x.willemsen@gsk.com",
                "first": "Arnold",
                "initial": "A.",
                "last": "Willemsen"
            },
            {
                "email": "chiranjiwi.x.bhusal@gsk.com",
                "first": "Chiranjiwi",
                "initial": "C.",
                "last": "Bhusal"
            },
            {
                "email": "daniela.x.toneatto@gsk.com",
                "first": "Daniela",
                "initial": "D.",
                "last": "Toneatto"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.10.096",
        "firstpage": "7609",
        "issn": "0264410X",
        "keywords": [
            "4CMenB",
            "Co-administration",
            "Infants",
            "MenACWY-CRM",
            "Meningococcal vaccination"
        ],
        "lastpage": "7617",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial"
    }
}